Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Blood (2023) 141 (8): 917–929.

https://doi.org/10.1182/blood.2022016846

Published: 2023

Includes: Supplemental data

Journal Articles

Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis

Sara Lecomte, Julien Devreux, Grégoire de Streel, Nicolas van Baren, Violaine Havelange, David Schröder, Noora Vaherto, Christophe Vanhaver, Christophe Vanderaa, Noémie Dupuis, Christian Pecquet, Pierre G. Coulie, Stefan N. Constantinescu, Sophie Lucas

Blood (2023) 141 (5): 490–502.

https://doi.org/10.1182/blood.2022017097

Published: 2023

Includes: Supplemental data

Journal Articles

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Blood (2022) 140 (17): 1845–1857.

https://doi.org/10.1182/blood.2021014586

Published: 2022

Includes: Supplemental data

Journal Articles

The 2 faces of ERK2 in MPNs

Violaine Havelange, Stefan N. Constantinescu

Blood (2022) 140 (4): 298–300.

https://doi.org/10.1182/blood.2022016536

Published: 2022

Journal Articles

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Blood (2021) 138 (Supplement 1): 700.

https://doi.org/10.1182/blood-2021-145379

Published: 2021

Journal Articles

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-139609

Published: 2020

Journal Articles

Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial

Blood (2019) 134 (Supplement_1): 1295.

https://doi.org/10.1182/blood-2019-124029

Published: 2019

Journal Articles

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

David A Sallman, MD, Jason B. Brayer, PhDMD, Xavier Poire, Violaine Havelange, Ahmad Awada, MD PhD, Philippe Lewalle, Kunle Odunsi, MD, Eunice S. Wang, MD, Caroline Lonez, PhD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Nathalie Braun, Anne Flament, MD, Ine Moors, MD, Tessa Kerre

Blood (2019) 134 (Supplement_1): 3826.

https://doi.org/10.1182/blood-2019-128020

Published: 2019

Journal Articles

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Blood (2019) 134 (Supplement_1): 4161.

https://doi.org/10.1182/blood-2019-127923

Published: 2019

Journal Articles

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Blood (2019) 133 (13): 1457–1464.

https://doi.org/10.1182/blood-2018-10-879866

Published: 2019

Includes: Supplemental data

Journal Articles

Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms

Cristina Mambet, Olga Babosova, Jean-Philippe Defour, Emilie Leroy, Laura Necula, Oana Stanca, Aurelia Tatic, Nicoleta Berbec, Daniel Coriu, Monika Belickova, Barbora Kralova, Lucie Lanikova, Jitka Vesela, Christian Pecquet, Pascale Saussoy, Violaine Havelange, Carmen C. Diaconu, Vladimir Divoky, Stefan N. Constantinescu

Blood (2018) 132 (25): 2695–2699.

https://doi.org/10.1182/blood-2018-04-843060

Published: 2018

Includes: Supplemental data

Journal Articles

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1398.

https://doi.org/10.1182/blood-2018-99-114747

Published: 2018

Journal Articles

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy

David A Sallman, MD, Tessa Kerre, MD, Xavier Poire, MD, Violaine Havelange, Philippe Lewalle, MD, Marco L. Davila, MD PhD, Eunice S. Wang, MD, Doreen Dekker, PhD, Sarah Snykers, PhD, Panagiota A. Sotiropoulou, PhD, Eytan Breman, Nathalie Braun, Caroline Lonez, PhD, Bikash Verma, MD DVM, Frédéric F. Lehmann, MD, Jason B. Brayer, PhDMD

Blood (2018) 132 (Supplement 1): 902.

https://doi.org/10.1182/blood-2018-99-111326

Published: 2018

Journal Articles

JAK2 R1063H Variant Enhances V617F Constitutive Signaling and Favors Development of Essential Thrombocythemia with Increased Hemoglobin and Neutrophils

Cristina Mambet, MD, Jean-Philippe Defour, BPharm, PhD, Olga Babosova, M.Sc., Emilie Leroy, Laura Necula, PhD, Oana Stanca, MD, Aurelia Tatic, MD, Daniel Coriu, MD, Monika Belickova, PhD, Barbora Kralova, MSc, Lucie Lanikova, PhD, Pascale Saussoy, Violaine Havelange, Carmen C. Diaconu, PhD, Vladimir Divoky, PhD, Stefan N Constantinescu, MD

Blood (2018) 132 (Supplement 1): 3066.

https://doi.org/10.1182/blood-2018-99-117019

Published: 2018

Journal Articles

Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry

Timothy Devos, Koen Theunissen, Fleur Samantha Benghiat, Alain Gadisseur, Stef Meers, Dominik Selleslag, Gaëtan Vanstraelen, Pierre Zachée, Marc André, Philippe Lewalle, MD, Mia Janssen, Rik Schots, Koen Van Eygen, Alain Kentos, Marie Lejeune, Agnes Triffet, Inge Vrelust, Carolina Kuipers, Violaine Havelange

Blood (2018) 132 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2018-99-114070

Published: 2018

Journal Articles

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux, Christoph Faul, Helmut Diedrich, Max S. Topp, Monika Brüggemann, Heinz-August Horst, Violaine Havelange, Julia Stieglmaier, Hendrik Wessels, Vincent Haddad, Jonathan E. Benjamin, Gerhard Zugmaier, Dirk Nagorsen, Ralf C. Bargou

Blood (2018) 131 (14): 1522–1531.

https://doi.org/10.1182/blood-2017-08-798322

Published: 2018

Includes: Supplemental data

Journal Articles

Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML

Blood (2017) 130 (Supplement 1): LBA-5.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-5.LBA-5

Published: 2017

Journal Articles

Clofarabin Added to Standard Treatment in Adult Patients with Newly Diagnosed ALL: First Results of the Randomized Phase III HOVON-100 Study

Blood (2017) 130 (Supplement 1): 2606.

https://doi.org/10.1182/blood.V130.Suppl_1.2606.2606

Published: 2017

Journal Articles

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Geert Huls, MD PhD, Dana Chitu, Violaine Havelange, Mojca Jongen-Lavrencic, MD PhD, Arjen van de Loosdrecht, Bart J. Biemond, MD PhD, Harm Sinnege, MDPhD, Beata Hodossy, Carlos Graux, Marinus van Marwijk Kooij, MD PhD, Okke de Weerdt, MD, Dimitri Breems, MD PhD, Saskia Klein, MD, Jurgen Kuball, MD, Gert J. Ossenkoppele, MD PhD, Bob Lowenberg, MD PhD, Edo Vellenga, MD

Blood (2017) 130 (Supplement 1): 463.

https://doi.org/10.1182/blood.V130.Suppl_1.463.463

Published: 2017

Journal Articles

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Blood (2017) 129 (12): 1636–1645.

https://doi.org/10.1182/blood-2016-10-740613

Published: 2017

Includes: Supplemental data

NARROW

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

The 2 faces of ERK2 in MPNs

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy

JAK2 R1063H Variant Enhances V617F Constitutive Signaling and Favors Development of Essential Thrombocythemia with Increased Hemoglobin and Neutrophils

Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML

Clofarabin Added to Standard Treatment in Adult Patients with Newly Diagnosed ALL: First Results of the Randomized Phase III HOVON-100 Study

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only